Manganese-enhanced Magnetic Resonance Imaging in Takotsubo Cardiomyopathy

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity of Edinburgh

About this trial

The goal of this research study is to further understand the physiological mechanisms involved in a heart condition called takotsubo cardiomyopathy, also known as broken heart syndrome. Furthermore, the investigators will be assessing the effects different cardiac medications have on these physiological mechanisms.

This will be achieved by performing cardiac MRI scans using a special dye called manganese. Manganese uptake in the heart is altered in patients with takotsubo cardiomyopathy. The investigators will study the effects that different cardiac medications have on manganese uptake.

Eligibility criteria

Qualifiers

Males and females >18 years of age

Clinical presentation of takotsubo cardiomyopathy

Have capacity to give formal consent

Disqualifiers

Unable to tolerate or contraindication to magnetic resonance imaging

Renal failure (estimated glomerular filtration rate <30 mL/min/1.73 m2) - this would be assessed by performing a blood test

Prior history of cardiomyopathy

Current pregnancy

Trial design

Treatments tested in this trial

  • Bisoprolol
  • Valsartan
  • sacubitril/ valsartan
  • Dapagliflozin (10mg Tab)
  • No medications

Treatment groups

100 Participants
are divided into 6 treatment groups

6

Treatment groups

See each treatment group below.

Sponsors and collaborators